Adrian is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian led multiple consultancy, licensing and M&A mandates. Notable deals include licensing transactions between MedGenesis and Pfizer, Esteve and Mundipharma, and M&A for a UK diagnostics business with Bruker and the sale of NanoSight to Spectris plc.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. He has held senior positions with Johnson & Johnson, drug discovery platform company Acumen Bioscience and the Healthcare Consultancy company Execute Technologies.

Adrian has over 30 years in the pharmaceutical, biotechnology and in vitro diagnostics sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

Stephen is a Managing Director of PharmaVentures. He joined PharmaVentures in 2012, after a long career in Healthcare Investment Banking. At PharmaVentures, Stephen has originated and worked on a number of strategic advisory, licensing and M&A mandates, assisting his clients find the optimal solutions to their challenges and opportunities.

Prior to joining PharmaVentures, Stephen worked as an equity research analyst at Teather & Greenwood, Commerzbank and Elixir Securities covering a range of domestic and international pharmaceutical and biotechnology companies. Subsequently Stephen moved into Corporate Finance roles within Elixir Securities and Matrix Securities, where he advised a number of public and private diagnostic, therapeutics and medical technology companies on fundraising and M&A. Before embarking on a career in the City, Stephen was instrumental in establishing Evaluate Pharma as one of the pre-eminent competitive intelligence tools in the healthcare industry.

He holds a PhD in Neurology from the University of Cambridge. Although he has a broad spectrum of experience across many sub-sectors of the Healthcare space, Stephen currently has a focus on Contract Research Organisations, Diagnostic, Medical Technologies and Therapeutics companies.

Soren is a Expert Advisor for PharmaVentures.

Soren excels in creating and unlocking value for clients through M&A, business development, and licensing. He has supported PharmaVentures since 2024, bringing over 15 years of global experience in the biopharma industry.

Soren’s successful industry and investment banking career, combined with his advisory and medical background, is crucial for understanding clients’ needs and providing optimised solutions.

Previously, Soren served as Chief Business Officer at the private equity-backed Essential Pharma. He also held the position of Commercial Director at the UK government’s biological manufacturing unit, Porton BioPharma, where he established new strategic collaborations and directed product development and manufacturing. Prior to this, Soren was part of Mitsubishi Tanabe and the Piramal Group.

Soren began his M&A career at Goldman Sachs, focusing on cross-border deal origination across the US, MENA, Europe, and Asia, before which he studied for a Bachelor of Medicine at the University of Sheffield and a PhD in Biotechnology from the University of Cambridge.

Nigel joined the team back in 2008 and brings to PharmaVentures’ clients specialist expertise in valuation methodologies, deal structuring modelling and pricing, and has extensive experience in major global pharmaceutical corporation site divestments in the USA and across Europe.

With a strong background in senior international commercial management roles in both diagnostics and biotechnology firms, Nigel brings insight into a breadth of life science industry sectors gained at drug testing specialists Syva Company, at Hoechst, US diagnostics leader Dade Behring, and as European Business Development Director for the California-based molecular biology company Cepheid.

With over 35 years experience in Life Sciences Nigel is the author of numerous Pharmaceutical/Biotech Industry reports, papers and articles, including most recently:-

The Royalty Rate Report 2012: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector; Cartwright & Borshell; ISBN: 978-0-9568270-2-9 Print

Approaches to Valuation of Pharmaceutical Licensing Deals; Ahmed & Borshell; Published by PharmaDeals 2012, ISBN 978-0-9568270-6-7 Print

Valuation benefits of structure-enabled drug discovery: Borshell & Congreve; Nature Reviews Drug Discovery, March 2011, Volume 10.

Pharmaceutical royalties in licensing deals: No place for the 25 per cent rule of thumb; Borshell & Dawkes, Journal of Commercial Biotechnology, Vol 16, No 1 (2010).

With over 35 years’ experience in the biologics industry Steve’s career has covered the manufacturing, process development, business development and general management of vaccine (human and animal), recombinant proteins, monoclonal antibodies and cell and gene therapy product supply. Steve has worked in both the CDMO and multi-product organisations and has extensive experience of microbial, yeast and mammalian cell culture systems ranging from less than 500mL to 12,000L scale using single use disposable and purpose designed and built stainless steel equipment.

A microbiologist by education Steve has lived and worked in the Netherlands. He has led technology transfer projects into, out of and within the UK, has worked as a process expert on facility design and build within and without of the UK and has been process/facility lead on several M&A assignments.

Ross joined PharmaVentures as a Business Analyst and has since been promoted to Director, with previous experience in diagnostic start-ups and commercialisation.

Prior to joining PharmaVentures, Ross worked at a multiplex immune-diagnostic start-up in New Zealand focused on both human and animal health. During this time he was involved across all areas of the business from communications, manufacturing, quality/regulatory affairs, and market analysis.

Ross holds a BSC(Hons) in Biotechnology and, a PGDip and Masters in Bioscience Enterprise from the University of Auckland.

At PharmaVentures, Gurdas is a key member of the M&A team, advising on both buy-side and sell-side transactions globally. He specialises in guiding companies to optimise their positioning for partnerships and M&A opportunities across diagnostics, pharmaceutical manufacturing, and healthcare services.

Before joining PharmaVentures, Gurdas gained extensive experience in investment banking, focusing primarily on the sell-side mandates across the healthcare, consumer and technology sectors. He has successfully executed deals spanning the healthcare industry, including medical technology, biopharmaceuticals, and cross-border CDMOs. In addition to his M&A expertise, Gurdas has a strong background in investor relations, strategy consulting, and working with start-ups.

Gurdas holds a Master's of Research from The University of Oxford, securing multiple research grants and having authored over 20 publications. He also earned a Bachelor's of Medicine and Surgery (MBBS) and a Bachelor's of Science in Medical Sciences from King's College London.

Lucie is an Analyst at PharmaVentures, bringing experience in both venture capital and pharmaceutical R&D.

Before joining PharmaVentures, Lucie worked within the healthcare team of a Family Office, where she supported strategic investments through market research and due diligence. She also gained hands-on experience in the pharmaceutical industry at UCB, where she focused on antibody discovery for rare diseases, contributing to advancements in targeted therapeutics, particularly in the development of monoclonal antibodies.

Lucie holds a BSc in Biomedical Science from King’s College London and an MSc in Immunology from Imperial College London. She is fluent in English and French.

Prior to joining PharmaVentures, Fabio worked as an Associate Consultant at Prescient Healthcare Group, focussing on competitive intelligence in oncology and haematology.

Fabio has been awarded a PhD in Tissue Engineering at University College London. During his studies, Fabio led the London Chapter of a Global Accelerator programme for seed-stage companies focussed on life sciences, digital health, clean-tech and advanced engineering, at Innovation Forum and joined Waimangu Ventures as an intern, backing the venture capital and consulting functions of the firm.

Fabio also holds a MSc in Molecular Medicine at Imperial College London and a BSc in Biotechnology from the University of Verona.

Sura comes with experience in early-stage biotech companies, particularly in their licensing efforts, strategic business planning, and internal business development activities.

Prior to joining PharmaVentures, Sura held roles in business development at early-stage therapeutics and diagnostics companies, contributing to key initiatives across various functions including fundraising, corporate restructuring (flip) and setup, alliance management, and business development strategy planning.

Sura holds an MPH in Epidemiology and Biostatistics from Tufts University and a BA in Biology from New York University (USA).

At PharmaVentures, Rebeca has supported biopharma companies and medical device manufacturers across M&A, fundraising, licensing and market access mandates.

Before joining the firm, Rebeca was part of a boutique consultancy providing strategic guidance to life sciences firms. Prior to this, she advised early-stage technologies at the commercialisation teams of Imperial College London and the Polsky Center Chicago, and also worked in the corporate commercial division at Samsung.

Rebeca completed her academic studies at the University of CEU San Pablo and at the University of Chicago. She also speaks Spanish, English, Italian and French.

Rohan is an Analyst in PharmaVentures’ Pricing & Market Access team, with a strong background in pharmaceutical consulting and international health policy.

Prior to joining PharmaVentures, Rohan held roles at Dolon and Pharma Business Partners, where he supported market access projects across Europe and the Middle East, focusing on pricing strategy, value communication, and HTA readiness. He also gained experience in commercial due diligence and R&D analysis during his time as a Research Analyst at McKinsey & Company.

Rohan holds a Master’s in International Health Policy from LSE and a Bachelor’s degree in Biotechnology Engineering. He is fluent in English and Hindi.

Paul joins PharmaVentures as a member of the Advisory Board based in Australia. Bringing over 25 years' board and executive experience across the life sciences, agricultural and not-for-profit sectors. His experience ranges from strategy formulation to capital raising, business development, technology commercialisation and sales & marketing.

Paul's work portfolio spans working as a Vice President in Animal Health at Agenix Ltd, Managing Director at Hatchtech Pty Ltd and Chief Executive Officer at Genetic Technologies Ltd. Paul is currently Chair of AdAlta Limited, Livac Pty Limited, and is Non-Executive Director of Sypharma Pty Limited. He has also launched a variety of products in Australia, the US and Asia, founded life sciences start-ups in the biologics area and worked in investment banking.

Paul graduated with a Bachelor of Veterinary Science from the University of Sydney. In addition, Paul also completed a postgraduate certificate in engineering at Swinburne University of Technology and Master of Business Administration degree at Macquarie University.

BPharm, LLM, MMkt, FAICD, FATSE, FACPP

Sue joined PharmaVentures as a member of the Advisory Board based in Australia.

Sue has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development. Sue has served as CEO and Board member of several ASX, AIM and NASDAQ listed companies in the Healthtech sector. She is currently Non-Executive Director at Rhythm Biosciences Ltd, Planet Innovation Holdings, Smartways Logistics, Viral Vector Manufacturing Pty Ltd, Australian Academy of Technology and Engineering (ATSE) and Omico. Sue is also appointed to several industry, academic and government advisory boards. Her broad commercial and technical experience is underpinned by a Bachelor of Pharmacy from the University of Queensland, a Master of Laws from Deakin University and a Master of Marketing from Melbourne Business School. She is also a Fellow of ATSE and Fellow/Graduate of Australian Institute of Company Directors (AICD).

Dr Christopher Berry previously worked on R&D Transactions within Sanofi R&D, where he was responsible for building research collaborations (ranging from material transfer agreements through to multi-scaffold drug discovery deals) in the areas of anti-infectives, biologics, and regenerative medicine, as well as for the Asia-Pacific Therapeutic Unit. In addition he was also responsible for opportunity scouting in the UK across all therapeutic areas. He had over 14 years experience in research alliance building and alliance management. He was previously Head of Thrombosis and Haematology in Synthélabo Recherche (one of Sanofi’s predecessor companies), which was the culmination of 16 years in discovery research which began in 1984 when he joined Synthélabo’s Pain and Inflammation group, after a brief flirtation with academic research. He is a member of the panel of KHIDI (Korean Health Industry Development Institute) Key Opinion Leaders in their business development support section. He obtained his PhD in Pharmacology at King’s College, London in 1981, and an MBA at the Open Business School in 2003.

Aki von Roy has over 30 years’ experience in big pharma and 16 years in biotech and has been involved in over 18 start-up or merger ventures as director or investor. These include Founder CEO of Proacta and CoDa Therapeutics and founding director of Corra Life Sciences (USA), Biomatter (NZ) and White Biotech (AUS). Aki is the former European president of Bristol-Myers Squibb, where he was responsible for US$ 2.2 billion in sales, more than 7,500 employees and some 40 subsidiaries. In 1997, he retired from BMS to establish RvR Associates, a private investment firm specialising in health and related matters. Former chairman of both private and publicly traded companies such as Genesis R&D, Phylogica, Vital Foods and Phytomedics Aki is now a Venture Partner at BioPacificVentures and an advisor to Direct Capital. He was previously a partner of Inventages (US$ 1.5 billion life science fund).

Frank has a 40-year track-record of success and innovation in the Pharmaceutical Industry working for Glaxo, BMS and Pliva. His main experiences cover Manufacturing, Quality Management, Commercial, Supply-Chain and Procurement (Strategic Sourcing) within the ethical & generic pharmaceutical and devices industry. He has formed and led teams in Europe/USA/Latin America and the Pacific Rim. Frank is a chemistry graduate from the University of Liverpool. Since joining PharmaVentures, Frank has opined on multiple divestment projects, including the recent sale of Novartis’ manufacturing plants to Siegfried.

Angela brings over a decade of experience in the pharmaceutical industry, specialising in Pricing and Market Access.

With her background as a qualified pharmacist, she has worked across both hospital and community settings in the UK before transitioning to her current focus in Market Access. Throughout her career, she has played a pivotal role in shaping market strategies, developing tailored messaging for payers and key opinion leaders (KOLs), and delivering innovative solutions to clients.

Her wealth of experience and deep understanding of market dynamics will further strengthen PharmaVentures’ ability to provide world-class Pricing and Market Access support to its global clients.